Tabula Rasa Healthcare

Popular Posts

• This answer contains spoilersExcellent question, and I have no idea why. But it also makes her the crucial player in a drama of violent passions and deadly desires.After plastic surgery transforms her face, Avery is mistaken for the glamorous, selfish wife of Tate Rutledge, the famous senatorial candidate and member of a powerful Texas dynasty.As she lays helpless in the hospital, Avery makes a shattering discovery: someone close to Tate planned to assassinate him. Now, to save him, she must live another woman\'s life - and risk her own. Mirror image twilight zone.

  MOORESTOWN, N.J., March 17, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, enters into an agreement with BioIntelliSense to distribute its BioSticker™, the first FDA-cleared, single-use device enabling 30 days of continuous vital sign monitoring.
  

  Real time Tabula Rasa HealthCare, Inc. Common Stock (TRHC) stock price quote, stock graph, news & analysis.

  The BioIntelliSense DaaS platform can be applied to a wide range of clinical use cases, including monitoring for the key symptoms associated with COVID-19¹.
  “BioSticker remote monitoring devices will add an additional layer of patient safety to MedWise™ and to the other software solutions we currently offer,” said TRHC Co-founder, Chairman and CEO Calvin H. Knowlton, PhD. “Our board-certified pharmacists and the medical teams at our client sites across the country will be able to monitor medication therapy along with vital signs, multi-parameter biometrics and symptomatic events for early detection. More informed medical care can only lead to better health outcomes.”
  BioSticker device data will populate TRHC’s unique medication safety platforms that identifiy accumulative multi-drug interactions and facilitate collaborative management of medications. TRHC’s board-certified pharmacists will access BioSticker device data to alert client clinicians to timely medication-related issues, enabling proactive intervention for safer medication use.

  “As TRHC serves a variety of healthcare clients, including the majority of PACE organizations in the United States, they are an outstanding partner for introduction of remote patient monitoring into the PACE market and beyond,” said BioIntelliSense CEO James Mault, MD. “The BioIntelliSense BioSticker device and data services are ideal for older adults with complex care needs. Tabula Rasa and its PACE clients will be able to more effectively monitor these complex patients through an effortless patient experience, enabling better care at a fraction of the cost of traditional remote patient monitoring.”

  

  PACE is a federal program providing comprehensive medical and social services to individuals 55 and older who are nursing-home eligible. The goal of PACE is to keep participants living in their own communities and to provide quality medical care. Currently, 131 PACE programs operate 263 PACE centers in 31 states, serving over 53,899 participants.

  ¹ as described by the Centers for Disease Control and Prevention (CDC.gov Coronavirus Symptoms)
  About Tabula Rasa HealthCare
  Tabula Rasa HealthCare (TRHC) is a leader in patient-specific,>For more information on how BioIntelliSense is redefining remote patient monitoring through advanced medical-grade and cost-effective services, please contact us at info@biointellisense.com or visit our website at BioIntelliSense.com.
  
  Forward-Looking Statements
  This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

  Contact
  TRHC Media Relations
  Amanda Bednar
  abednar@TRHC.com
  T:856-912-57147

  Dianne Semingson
  dsemingson@TRHC.com
  T: 215-870-0829

  Investors
  Frank Sparacino
  fsparacino@trhc.com
  Office 866.648.2767

  Victory Capital Management Inc. boosted its stake in Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 42.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,393 shares of the company’s stock after acquiring an additional 1,903 shares during the period. Victory Capital Management Inc.’s holdings in Tabula Rasa HealthCare were worth $311,000 as of its most recent SEC filing.

  A number of other hedge funds also recently modified their holdings of the stock. California State Teachers Retirement System increased its position in Tabula Rasa HealthCare by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 30,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 363 shares during the period. Oregon Public Employees Retirement Fund increased its position in Tabula Rasa HealthCare by 8.2% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,919 shares of the company’s stock worth $385,000 after purchasing an additional 600 shares during the period. State of Tennessee Treasury Department increased its position in Tabula Rasa HealthCare by 8.7% during the 4th quarter. State of Tennessee Treasury Department now owns 8,392 shares of the company’s stock worth $408,000 after purchasing an additional 674 shares during the period. Taylor Wealth Management Partners increased its position in Tabula Rasa HealthCare by 0.7% during the 4th quarter. Taylor Wealth Management Partners now owns 117,554 shares of the company’s stock worth $5,723,000 after purchasing an additional 788 shares during the period. Finally, Swiss National Bank increased its position in Tabula Rasa HealthCare by 2.3% during the 4th quarter. Swiss National Bank now owns 35,900 shares of the company’s stock worth $1,748,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

  Shares of Tabula Rasa HealthCare stock opened at $48.63 on Friday. The business has a 50-day moving average of $54.08 and a 200-day moving average of $50.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.36 and a quick ratio of 2.27. The company has a market capitalization of $1.11 billion, a PE ratio of -30.78 and a beta of 1.24. Tabula Rasa HealthCare Inc has a 1-year low of $33.04 and a 1-year high of $69.72.

  Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.04 by $0.09. Tabula Rasa HealthCare had a negative net margin of 11.39% and a negative return on equity of 1.51%. The business had revenue of $73.22 million for the quarter, compared to analysts’ expectations of $72.67 million. During the same quarter last year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts expect that Tabula Rasa HealthCare Inc will post -0.15 earnings per share for the current fiscal year.

  In other news, CEO Calvin H. Knowlton sold 802 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $47.75, for a total transaction of $38,295.50. Following the transaction, the chief executive officer now owns 774,079 shares of the company’s stock, valued at $36,962,272.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Orsula V. Knowlton sold 628 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $47.75, for a total transaction of $29,987.00. Following the transaction, the president now directly owns 751,647 shares in the company, valued at approximately $35,891,144.25. The disclosure for this sale can be found here. Insiders have sold 37,845 shares of company stock worth $1,804,184 in the last ninety days. Corporate insiders own 11.80% of the company’s stock.

  Several equities research analysts have recently commented on the company. ValuEngine lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 18th. Piper Sandler boosted their price target on Tabula Rasa HealthCare from to in a research note on Friday, February 28th. BidaskClub raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Wednesday, March 25th. TheStreet raised Tabula Rasa HealthCare from a “d+” rating to a “c-” rating in a research note on Friday, February 7th. Finally, William Blair reissued an “outperform” rating on shares of Tabula Rasa HealthCare in a research note on Friday, January 17th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Tabula Rasa HealthCare currently has an average rating of “Buy” and an average price target of $65.88.

  About Tabula Rasa HealthCare

  

  Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company\'s proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients\' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

  Read More: What are popular green investing opportunities?

  Want to see what other hedge funds are holding TRHC?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare Inc (NASDAQ:TRHC).

  ,753000000,725,null,null,\'5',\'Sebastian Deyzel\',null,null,2,null,null,null,\'za\',null,2,null,null,null,\'very good game but the next brand should have the feature of mini militia which is connection through lan Wi-Fi pls correct that Nice game!!! ,873000000,54,null,null,\'2',\'Faz za\',null,null,2,null,null,null,\'World\',null,2,null,null,null,\'very interesting game with great sound. Fun to play!!!\' Metal reaper online gameplay 2.

  Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts\' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com\'s FREE daily email newsletter.

  ...'>Tabula Rasa Healthcare(30.03.2020)

• This answer contains spoilersExcellent question, and I have no idea why. But it also makes her the crucial player in a drama of violent passions and deadly desires.After plastic surgery transforms her face, Avery is mistaken for the glamorous, selfish wife of Tate Rutledge, the famous senatorial candidate and member of a powerful Texas dynasty.As she lays helpless in the hospital, Avery makes a shattering discovery: someone close to Tate planned to assassinate him. Now, to save him, she must live another woman\'s life - and risk her own. Mirror image twilight zone.

  MOORESTOWN, N.J., March 17, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, enters into an agreement with BioIntelliSense to distribute its BioSticker™, the first FDA-cleared, single-use device enabling 30 days of continuous vital sign monitoring.
  

  Real time Tabula Rasa HealthCare, Inc. Common Stock (TRHC) stock price quote, stock graph, news & analysis.

  The BioIntelliSense DaaS platform can be applied to a wide range of clinical use cases, including monitoring for the key symptoms associated with COVID-19¹.
  “BioSticker remote monitoring devices will add an additional layer of patient safety to MedWise™ and to the other software solutions we currently offer,” said TRHC Co-founder, Chairman and CEO Calvin H. Knowlton, PhD. “Our board-certified pharmacists and the medical teams at our client sites across the country will be able to monitor medication therapy along with vital signs, multi-parameter biometrics and symptomatic events for early detection. More informed medical care can only lead to better health outcomes.”
  BioSticker device data will populate TRHC’s unique medication safety platforms that identifiy accumulative multi-drug interactions and facilitate collaborative management of medications. TRHC’s board-certified pharmacists will access BioSticker device data to alert client clinicians to timely medication-related issues, enabling proactive intervention for safer medication use.

  “As TRHC serves a variety of healthcare clients, including the majority of PACE organizations in the United States, they are an outstanding partner for introduction of remote patient monitoring into the PACE market and beyond,” said BioIntelliSense CEO James Mault, MD. “The BioIntelliSense BioSticker device and data services are ideal for older adults with complex care needs. Tabula Rasa and its PACE clients will be able to more effectively monitor these complex patients through an effortless patient experience, enabling better care at a fraction of the cost of traditional remote patient monitoring.”

  

  PACE is a federal program providing comprehensive medical and social services to individuals 55 and older who are nursing-home eligible. The goal of PACE is to keep participants living in their own communities and to provide quality medical care. Currently, 131 PACE programs operate 263 PACE centers in 31 states, serving over 53,899 participants.

  ¹ as described by the Centers for Disease Control and Prevention (CDC.gov Coronavirus Symptoms)
  About Tabula Rasa HealthCare
  Tabula Rasa HealthCare (TRHC) is a leader in patient-specific,>For more information on how BioIntelliSense is redefining remote patient monitoring through advanced medical-grade and cost-effective services, please contact us at info@biointellisense.com or visit our website at BioIntelliSense.com.
  
  Forward-Looking Statements
  This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

  Contact
  TRHC Media Relations
  Amanda Bednar
  abednar@TRHC.com
  T:856-912-57147

  Dianne Semingson
  dsemingson@TRHC.com
  T: 215-870-0829

  Investors
  Frank Sparacino
  fsparacino@trhc.com
  Office 866.648.2767

  Victory Capital Management Inc. boosted its stake in Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 42.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,393 shares of the company’s stock after acquiring an additional 1,903 shares during the period. Victory Capital Management Inc.’s holdings in Tabula Rasa HealthCare were worth $311,000 as of its most recent SEC filing.

  A number of other hedge funds also recently modified their holdings of the stock. California State Teachers Retirement System increased its position in Tabula Rasa HealthCare by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 30,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 363 shares during the period. Oregon Public Employees Retirement Fund increased its position in Tabula Rasa HealthCare by 8.2% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,919 shares of the company’s stock worth $385,000 after purchasing an additional 600 shares during the period. State of Tennessee Treasury Department increased its position in Tabula Rasa HealthCare by 8.7% during the 4th quarter. State of Tennessee Treasury Department now owns 8,392 shares of the company’s stock worth $408,000 after purchasing an additional 674 shares during the period. Taylor Wealth Management Partners increased its position in Tabula Rasa HealthCare by 0.7% during the 4th quarter. Taylor Wealth Management Partners now owns 117,554 shares of the company’s stock worth $5,723,000 after purchasing an additional 788 shares during the period. Finally, Swiss National Bank increased its position in Tabula Rasa HealthCare by 2.3% during the 4th quarter. Swiss National Bank now owns 35,900 shares of the company’s stock worth $1,748,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

  Shares of Tabula Rasa HealthCare stock opened at $48.63 on Friday. The business has a 50-day moving average of $54.08 and a 200-day moving average of $50.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.36 and a quick ratio of 2.27. The company has a market capitalization of $1.11 billion, a PE ratio of -30.78 and a beta of 1.24. Tabula Rasa HealthCare Inc has a 1-year low of $33.04 and a 1-year high of $69.72.

  Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.04 by $0.09. Tabula Rasa HealthCare had a negative net margin of 11.39% and a negative return on equity of 1.51%. The business had revenue of $73.22 million for the quarter, compared to analysts’ expectations of $72.67 million. During the same quarter last year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts expect that Tabula Rasa HealthCare Inc will post -0.15 earnings per share for the current fiscal year.

  In other news, CEO Calvin H. Knowlton sold 802 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $47.75, for a total transaction of $38,295.50. Following the transaction, the chief executive officer now owns 774,079 shares of the company’s stock, valued at $36,962,272.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Orsula V. Knowlton sold 628 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $47.75, for a total transaction of $29,987.00. Following the transaction, the president now directly owns 751,647 shares in the company, valued at approximately $35,891,144.25. The disclosure for this sale can be found here. Insiders have sold 37,845 shares of company stock worth $1,804,184 in the last ninety days. Corporate insiders own 11.80% of the company’s stock.

  Several equities research analysts have recently commented on the company. ValuEngine lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 18th. Piper Sandler boosted their price target on Tabula Rasa HealthCare from to in a research note on Friday, February 28th. BidaskClub raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Wednesday, March 25th. TheStreet raised Tabula Rasa HealthCare from a “d+” rating to a “c-” rating in a research note on Friday, February 7th. Finally, William Blair reissued an “outperform” rating on shares of Tabula Rasa HealthCare in a research note on Friday, January 17th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Tabula Rasa HealthCare currently has an average rating of “Buy” and an average price target of $65.88.

  About Tabula Rasa HealthCare

  

  Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company\'s proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients\' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

  Read More: What are popular green investing opportunities?

  Want to see what other hedge funds are holding TRHC?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare Inc (NASDAQ:TRHC).

  ,753000000,725,null,null,\'5',\'Sebastian Deyzel\',null,null,2,null,null,null,\'za\',null,2,null,null,null,\'very good game but the next brand should have the feature of mini militia which is connection through lan Wi-Fi pls correct that Nice game!!! ,873000000,54,null,null,\'2',\'Faz za\',null,null,2,null,null,null,\'World\',null,2,null,null,null,\'very interesting game with great sound. Fun to play!!!\' Metal reaper online gameplay 2.

  Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts\' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com\'s FREE daily email newsletter.

  ...'>Tabula Rasa Healthcare(30.03.2020)